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Introduction: Malignant pleural mesothelioma (MPM) is a rare 
malignant disease, and the understanding of molecular pathogenesis 
has lagged behind other malignancies.
Methods: A series of 123 formalin-fixed, paraffin-embedded tissue 
samples with clinical annotations were retrospectively tested with a 
commercial library kit (Ion AmpliSeq Cancer Hotspot Panel v.2, Life 
Technologies, Grand Island, NY) to investigate 50 genes plus other 
two, BRCA1-associated protein-1 (BAP-1) and neurofibromatosis-2 
(NF2), frequently altered in MPM. DNA was obtained from tissues 
after manual microdissection and enriched for at least 50% cancer 
cells. Variations affecting protein stability or previously correlated to 
cancer, more frequently identified (≥25 patients with at least 10% of 
allelic frequency), were subsequently evaluated by Sanger sequenc-
ing. Immunohistochemistry staining for BAP1 and NF2 proteins was 
also performed.
Results: The commonest genetic variations were clustered in two 
main pathways: the p53/DNA repair (TP53, SMACB1, and BAP1) 
and phosphatidylinositol 3-kinase–AKT pathways (PDGFRA, KIT, 
KDR, HRAS, PIK3CA, STK11, and NF2). PIK3CA:c.1173A>G 
mutation, STK11:rs2075606 (T>C), or TP53:rs1042522 (Pro/Pro) 
was significantly associated with time to progressive disease (TTPD; 
all p values < 0.01). Furthermore, the accumulation of genetic altera-
tions correlated with shorter TTPD and reduced overall survival 
(TTPD p value = 0.02, overall survival p value = 0.04). BAP1 genetic 
variations identified were mainly located in exons 13 and 17, and 
BAP1 nonsynonymous variations were significantly correlated with 
BAP1 protein nuclear localization.
Conclusion: Next-generation sequencing was applied to a relatively 
large retrospective series of MPM using formalin-fixed, paraffin-
embedded archival material. Our results indicate a complex muta-
tional landscape with a higher number of genetic variations in the 
p53/DNA repair and phosphatidylinositol 3-kinase pathways, some 
of them with prognostic value.
Key Words: Malignant pleural mesothelioma, Genetic variation, 
Next-generation sequencing, Genetic characterization, BAP1 gene, 
NF2 gene, PI3K gene.
(J Thorac Oncol. 2015;10: 492–499)
Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options.1 Most of newly 
diagnosed patients present with advanced disease and first-line 
chemotherapy extends survival of 3 months, whereas there is no 
approved agent for second-line chemotherapy.2 Prognostication 
in MPM has been approached by studying several clinical vari-
ables, radiological parameters at presentation and molecular/
pathological findings, mainly in retrospective studies with a 
limited number of patients, and most of the findings remain not 
validated.3 Prognostic scoring systems have been proposed, but 
they are not routinely implemented in daily clinical practice.4 
Moreover, even in the context of a specific MPM histological 
subtype, there are differences in the clinical course including 
long surviving patients, whose tumors apparently do not differ 
morphologically from conventional, highly aggressive MPM.5
According to the COSMIC database, the most fre-
quently mutated genes in MPM include CDKN2A, neurofibro-
matosis-2 (NF2), and BRCA1-associated protein-1 (BAP-1).6–8 
BAP1 germline gene mutations have been identified and asso-
ciated with a cancer syndrome that includes MPM, ocular or 
cutaneous melanoma, and other cancers.9–11
The expanding application of next-generation sequenc-
ing (NGS) offers the opportunity to accurately map the type 
and extent of genetic variations in MPM and to provide 
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correlation with morphological and prognostic parameters of 
potential therapeutic relevance.
In this retrospective study, 123 formalin-fixed, 
paraffin-embedded (FFPE) MPM tissue samples with 
clinical annotates, collected from two institutions, were 
analyzed by NGS with the aim of generating knowledge 
about tumor-specific genetic profile and to investigate 
any potential correlation of the most frequently detected 
genetic variations with clinical pathological variables and 
survival outcomes.
PATIENTS AND METHODS
Patients and Tissue Samples
Between November 2003 and December 2012, 123 
consecutive cases of MPM diagnosed at two institutions 
(Orbassano, n = 93; Alessandria, n = 30) with enough left-
over tissue available and detailed clinical annotates were retro-
spectively collected. The available tissues were FFPE biopsy 
samples obtained through pleuroscopy or videothoracoscopy 
from patients (pts) with stages III (limited to T3, any stage) 
and IV12 MPM, treated with platinum-based plus pemetrexed 
chemotherapy. None of the patients received surgery or radia-
tion therapy at any time. During chemotherapy, patients were 
evaluated for tumor response by chest-computed tomography 
scans every two cycles and during the follow up according 
to local policy using modified response evaluation criteria in 
solid tumors.13
All samples were reviewed and classified accord-
ing to the World Health Organization classification.5 
Informed consent was obtained from each patient, and the 
Institutional Review Board of the participating institutions 
approved the study. All samples were de-identified, and 
cases anonymized by a pathology staff member were not 
involved in the study.
Genomic DNA Extraction
DNA was obtained from tissues after manual microdis-
section with enrichment for neoplastic cells (at least 50%). 
Genomic DNA (gDNA) was extracted using QIAamp DNA 
FFPE Tissue Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions. gDNA was quantified using fluo-
rometer Qubit platform (Invitrogen, Carlsbad, CA), and the 
DNA quality was tested amplifying a 200-base pair region of 
the β-actin gene.
Next-Generation Sequencing
NGS analyses were performed on the Ion Torrent 
Personal Genome Machine (PGM, Life Technologies, Grand 
Island, NE). Tumor samples were tested with a commercial 
library kit (Ion AmpliSeq Cancer Hotspot Panel v.2) to inves-
tigate 50 cancer-associated genes (see Supplemental Table, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A753). In addition, because the panel did not include BAP1 
and NF2, two genes frequently mutated in MPM, a custom 
NGS library was designed including 58 amplicons, covering 
all the exonic sequences. Each amplicon library was generated 
starting from 10 ng of gDNA, as indicated by the manufacturer, 
and barcoded with Ion Xpress Barcode Adaptors Kit (Life 
Technologies). DNA library quantification was performed 
using the polymerase chain reaction (PCR) quantification kit 
and the 7900HT real time PCR system (Life Technologies), 
diluted in nuclease-free water to obtain a final concentration of 
100 pM. Emulsion PCR was performed on Ion PGM Template 
OneTouch 2 system (Life Technologies). The quality of the 
emulsion PCRs was measured using the Qubit IonSphere 
Quality control kit (Life Technologies). Ionsphere particles 
with DNA were isolated and sequenced on Ion 316 chip using 
the Ion PGM Sequencing 200 Kit (Life Technologies). Only 
sample sequences with at least a quality score of AQ20 (1 mis-
aligned base per 100 bases) were considered for further analy-
ses. The coverage target for each sample was set at a minimum 
average deep of 100 reads for each amplicon.
Variant Caller and Annotation
Variant Caller plugin included in Torrent Suite Software 
(v.3.6; Life Technologies) was used to identify variations in tar-
get regions, and genetic annotation was performed with Annovar 
software (http://www.openbioinformatics.org/annovar/). Each 
of the identified genetic variation was coded according to “plus 
strand” of Human Genome assembly hg19. More frequent 
genetic variations (≥25 patients with ≥10% allele frequency 
[AF]) affecting protein stability or previously correlated to can-
cer by COSMIC database (v.64) were validated by means of 
Sanger sequencing.
BAP1 and NF2 immunohistochemistry
FFPE tissue blocks were cut into serial 4-μm thick 
sections and collected onto charged slides for staining. 
Immunohistochemistry (IHC) reaction was performed as 
previously described.11 Primary antibodies used were as fol-
lows: anti-BAP1 (mouse monoclonal, clone C-4, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) and anti-NF2 (rabbit poly-
clonal, code A-19, Santa Cruz Biotechnology). Stromal endo-
thelial cells were the internal reference control for BAP1; for 
NF2 an external control of colon cancer was used as indicated by 
manufacturer’s instructions. The BAP1 staining was considered 
positive in the presence of a nuclear immunoreactivity, whereas 
NF2 displayed a cytoplasmic staining. The semiquantitative 
H-score evaluation method was used, as previously described.14
Statistical Analysis
Statistical correlation between gene variations with AF 
≥10% and clinical pathological features were investigated by 
Fisher exact test. Time to progressive disease (TTPD) was 
defined as the time from the diagnosis until the first evidence 
of disease progression. Overall survival (OS) was calculated 
from the date of diagnosis to death or last follow up. The log 
rank test was used to assess differences between groups. The 
Cox proportional hazards regression model was performed 
to analyze independent predictors of MPM and OS. Only the 
variables that were found to be significant in the univariate 
analyses (p < 0.05) were entered into the multivariable anal-
ysis to determine the most significant factor for predicting 
disease outcome. Statistical analysis was elaborated using R 
statistical software (http://www.r-project.org/).
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RESULTS
Patients
MPM tissue samples included 96 epithelioid, 22 bipha-
sic and 5 sarcomatous subtypes; 86 were males and 37 females. 
Median age at diagnosis was 66.5 years (range 36–82). Sixty-
one patients were current smokers, 56 were never or former 
smokers; for six patients the smoking status information was 
not available. After a mean follow up of 21.1 months, 99 of 
123 were died. At the univariate analyses, only age and his-
tological subtype were significantly associated with disease 
outcomes.
Gene Variations in the 52 
Cancer Associated Genes
DNA was successfully amplified from all samples. The 
large number of variations detected in our study requested 
the selection of an arbitrary cutoff value, mainly based on 
the amount of generated NGS data and the sample size 
of our population. Based on these assumptions, the genes 
mutated in at least 20% of our samples (corresponding to 
25 patients) was chosen. Twenty genes harbored variations 
(including intronic, synonymous, nonsynonymous, and 
regulative) in more than 25 patients with ≥10% AF. Some 
of these genes had a large number of mutations, and the 
nonsynonymous were strongly underrepresented (Fig. 1). 
A small number of samples (Fig. 1) showed a high varia-
tion rate in the top 20 genes. The other 32 genes included 
K/N-RAS, PTEN, ERBB2, AKT1, B-RAF, and FGFR1/2 
genes reported to be altered in other types of tumors (see 
Supplemental Table, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A753).
BAP1 genetic variations were mainly located in exon 
13 accounting for 54 variations detected in 47 patients (38%) 
and in exon 17 (44 variations in 31 patients, 25%). On the 
contrary, variations identified in NF2 gene were distributed 
homogeneously throughout the sequenced regions (Fig. 2; see 
Supplemental Tables, Supplemental Digital Content 1, http://
links.lww.com/JTO/A753 and Supplemental Digital Content 
2, http://links.lww.com/JTO/A754).
BAP1 and NF2 IHC
BAP1 IHC expression was assessed in 116 of the 123 
considered cases. Sixty tumors (52%) had nuclear expression 
in mesothelial neoplastic cells with diffuse and intense stain-
ing; 13 of 116 (11%) did not show nuclear positivity but had 
a weak granular cytoplasmic positivity, whereas 43 of 116 
(37%) were completely negative in tumor cells with a positiv-
ity in stromal cells, used as an internal control. Nuclear BAP1 
protein expression was correlated to nonsynonymous varia-
tions detected by BAP1/NF2 custom panel. The lack of BAP1 
IHC nuclear expression significantly correlated with the 
detection of nonsynonymous variations with allelic frequency 
of 10% or 25% (Fisher test p value < 0.01 for both allelic fre-
quencies; Fig. 3). No correlations were found between BAP1 
protein loss and each of the available clinical pathological 
characteristics.
NF2 reactivity was positive in the cytoplasm in 107 
of 116 cases (92%) ranging from weak to intense diffuse 
staining and with an heterogeneous pattern of positivity in 
different tumor areas (median H-score value = 90, range 10–
300); 9 of 116 cases (8%) were completely negative. There 
was no correlation between NF2 protein expression and 
NF2 gene variations detected by NGS or clinical pathologi-
cal characteristics. In the 62 tumor samples harboring NF2 
gene nonsynonymous variations (see Supplemental Tables, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A753 and Supplemental Digital Content 2, http://links.lww.
com/JTO/A754), IHC loss of NF2 protein (H-score = 0) was 
reported in nine cases only.
FIGURE 1.  Summary of genetic variations identified by next-generation sequencing. In the left panel, the variations identified 
in the top 20 genes (≥25 patients mutated with at least 10% of allelic frequency) are summarized: in red the malignant pleural 
mesothelioma (MPM) samples (pts) with at least a variation (intronic, synonymous, nonsynonymous, and regulative), whereas 
in blue the MPM samples with at least one nonsynonymous/regulative variation in the top 20 genes. The right panel shows the 
heatmap of MPM samples with only the nonsynonymous/regulative variations at ≥10% AF. The blue blocks identify variations, 
although the color intensity is proportional to number of mutations observed in each MPM sample.
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Selection of Genes and Validation of 
NGS Data using Sanger Sequencing
All genetic variations documented in at least 25 patients 
and with ≥10% AF were further evaluated according to two 
main criteria: (1) the presence of genetic variation in COSMIC 
database and associated with cancer or/and (2) the detection 
of a statistical association with clinical pathological charac-
teristics. Nine variations detected at NGS in ≥25 patients and 
with ≥10% AF were further analyzed by Sanger sequencing 
(see Supplemental Table, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A753). In eight out of these genes 
(STK11, HRAS, SMARCB1, PDGFRA, TP53, PIK3CA, KIT, 
and KDR), the genetic variations were confirmed (Table 1), 
whereas that initially identified in the APC gene was an arti-
fact because of software bias.
The most frequent nonsynonymous genetic varia-
tions identified in our tumor samples were mainly two single 
nucleotide polymorphisms (SNPs) within the CSFR1 gene, 
reported with the same allelic frequency as indicated in 1000 
genomes database, not previously correlated with cancer and 
not enriched in MPM. No correlation with clinical pathologi-
cal characteristics was identified.
Those genetic alterations not affecting protein expression, 
initially identified by NGS and then validated, had a high inci-
dence. Three of these variations, all in heterozygosis, already 
associated to cancer and annotated in COSMIC database, 
have the following IDs: COSM249860 (HRAS p.H27H, 58% 
patients, mean AF 54%), COSM1090 (SMARCB1 intronic, 
31% patients, mean AF 51%), and COSM22413 (PDGFRA 
p.V824V, 23% patients, mean AF 52%). The polymorphism 
rs2075606 (T>C) identified in the STK11 intron (43% MPM 
samples, mean AF 54%) and not yet correlated to cancer was 
significantly associated with early disease progression (see 
Supplemental Fig., Supplemental Digital Content 3, http://
links.lww.com/JTO/A755], log-rank p value less than 0.01).
Similarly, a significant association between some of 
the validated nonsynonymous genetic variations (Fig. 4) and 
disease progression was identified. In the TP53 gene, the 
polymorphism rs1042522 was C:C (corresponding to amino 
acids arginine/arginine [Arg/Arg]) in 33% of considered 
FIGURE 2.  BAP1/NF2 panel: BAP1 variations were 
enriched mainly in exons 13 and 17. Loci of BAP1 
and NF2 are shown. The blue blocks represent the 
exons, whereas the red blocks indicated the regions 
amplified and sequenced with BAP1/NF2 custom 
panel. The red and yellow circles indicate the 
regions with at least 10 variations (red) or mutated 
samples (yellow). The size of circles is proportional 
to variations/samples counted for each region. The 
genetic variations identified in NF2 were distributed 
throughout the sequenced exons. Conversely, the 
BAP1 genetic variations were enriched mainly in 
exons 13 and 17.
FIGURE 3.  BAP1 nuclear protein localization cor-
relates with next-generation sequencing results. 
Top panel: contingency tables show the correla-
tion between nuclear BAP1 protein expression and 
nonsynonymous variations detected by BAP1/NF2 
custom panel. The lack of BAP1 protein expression 
was significantly correlated with the detection of 
nonsynonymous variations identified with allelic 
frequency of 10% or 25% (Fisher test p value < 0.01 
for both 10% and 25% of allelic frequency). Bottom 
panel: BAP1 immunohistochemistry. A, malignant 
pleural mesothelioma with nuclear expression of 
BAP1 (arrow). B, malignant pleural mesothelioma 
with loss of BAP1 nuclear expression in neoplastic 
cells (thick arrow) and maintained BAP1 expression 
in endothelial and stromal normal cells (thin arrows; 
immunoperoxidase staining, ×400).
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samples, C:G (arginine/proline [Arg/Pro]) in 61%, and G:G in 
6% (proline/proline [Pro/Pro]). A correlation between TP53 
rs1042522 genotype, TTPD, and OS was documented; the 
upper right graphs in Figure 4 show the Kaplan–Meier curves 
according to NGS data, whereas the lower graphs those using 
Sanger sequencing data. In both groups, estimated survival 
curves show the same trend. With NGS data, a strong cor-
relation between the G:G genotype and early TTPD (median 
8.1 months), compared with C:C and C:G genotypes (median 
21.5 and 15.6 months, respectively), was observed (log-rank p 
value < 0.01), whereas the association with OS was of border-
line significance (p value = 0.042). In the 60 cases validated 
at Sanger sequencing, the association with TTPD was main-
tained (p value = 0.042), whereas there was only a trend for 
OS (p value = 0.087).
In 31% of the MPM samples, the PIK3CA mutation 
I391M, corresponding to COSM328028 (c.1173A>G), was 
detected and associated with disease progression after two 
cycles (Fisher test p value = 0.03), although the median TTPD 
was not significantly different (log-rank p value = 0.1). With 
the two sequencing methods, concordant results were reported 
when the allelic frequency at NGS was ≥15% (Fig. 4B).
Multivariable Cox regression analysis indicated STK11 
(rs2075606) and TP53 (rs1042522; G:G genotype) as indepen-
dent predictors of TTPD (STK11: hazard ratio [HR] = 1.78; 
95% confidence interval [CI] = [1.12–2.81]; p value = 0.01 
and TP53: HR = 3.9; 95% CI = [1.54–9.79]; p value <0.01). 
STK11 and TP53 were also independently associated to OS 
(STK11: HR = 1.55; 95% CI = [1.04–2.33]; p value = 0.03 and 
TP53: HR = 2.65; 95% CI = [0.15–6.10]; p value = 0.02).
Patients with multiple validated variations (STK11, 
TP53, PIK3CA, KIT, and KDR) had a shorter TTPD and 
reduced OS (Fig. 5). Interestingly, an inverse correlation 
between TTPD or OS and the number of allelic variations (0, 
1, 2, and ≥3 genetic variations) in these genes was observed 
(TTPD log-rank p value = 0.02; OS log-rank p value=0.04; 
Fig. 5).
DISCUSSION
Over the past few years, NGS boosted biological and 
biomedical knowledge facilitating multigene mutational pro-
filing using extremely small amount of DNA, available also by 
FFPE samples. The expanding application of NGS techniques 
has the potential for accurately mapping the type and extent of 
gene mutations in MPM.
In this retrospective study in MPM, the feasibility of 
assessing mutational changes by NGS using FFPE tissue sam-
ples was investigated using a commercially available panel of 
key cancer-associated genes. Our results showed that NGS 
was feasible, despite the disadvantage of DNA fragmentation 
and reduced DNA amounts obtained from FFPE samples.
Our data do not indicate the presence of a specific muta-
tion in a single driver gene, favoring the hypothesis of the accu-
mulation of several nondriver mutations that could explain the 
extremely long latency phase of this asbestos-related disease.
Most frequently identified and validated genetic varia-
tions were clustered in two main and partially overlapped 
pathways: the p53/DNA repair and the receptor tyrosine 
kinase–phosphatidylinositol 3-kinase (PI3K)–AKT pathways 
(see Supplemental Fig., Supplemental Digital Content 4, 
http://links.lww.com/JTO/A756).
In the p53/DNA pathway, genetic variations were 
mainly identified in TP53, SMARCB1, BAP1, and CDKN2A.15 
Interestingly, TP53 and CDKN2A had the highest nonsynony-
mous/synonymous genetic variations ratio (see Supplemental 
Table, Supplemental Digital Content 1, http://links.lww.
com/JTO/A753), suggesting that mutations in this pathway 
could be relevant for MPM carcinogenesis and/or evolu-
tion. Furthermore, TP53 SNP rs1042522 was observed, and 
the Pro/Pro genotype was associated to shorter TTPD and 
reduced OS (Fig 4A, p value <0.01 and <0.04, respectively). 
According to previously reported data, the Arg72 genotype 
induces more efficiently apoptosis, whereas the Pro72 geno-
type preferentially induces G1 arrest, leading to the activation 
of p53-dependent DNA repair.16,17 Early studies indicate that 
patients with the Pro/Pro genotype are more prone to have pri-
mary resistance to cisplatin-based chemotherapy, compared 
with those with Arg/Arg or Arg/Pro variants.18,19 In advanced 
gastric cancer patients treated with paclitaxel and cisplatin, the 
TP53 codon 72 SNP was predictive of chemotherapy response 
and correlated with TTPD.20
As expected, several genetic variations were docu-
mented in the BAP1 gene. Two hotspot regions with genetic 
variations were identified: one in exon 13 (54 variations, 
TABLE 1.  Genetic Variations Identified by Next-Generation Sequencing and Validate by Sanger Sequencing in Malignant 
Pleural Mesothelioma Patient Cohort
Amplicon Nucleotide more Freq. Variated Patients with Var. (≥10% AF) Cosmic ID Allelic Freq. (Mean, Median)
Synonymous or Intronic Genetic Variations
  STK11.2 chr19:1220321 — — 0.54, 0.52
  HRAS.1 chr11:534242 72 (58%) COSM249860 0.54, 0.48
  SMARCB1.4 chr22:24176287 38 (31%) COSM1090 0.51, 0.46
  PDGFRA.4 chr4:55152040 28 (23%) COSM22413 0.52, 0.47
Nonsynonymous genetic variations
  TP53.2 chr17:7579472 70 (57%) — 0.84, 0.90
  PIK3CA.4 chr3:178927410 31 (25%) COSM328028 0.48, 0.53
  KIT.3 chr4:55593464 32 (26%) COSM28026 0.50, 0.49
  KDR.3 chr4:55972974 48 (39%) COSM149673 0.52, 0.51
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38% patients) and the other in exon 17 (44 variations, 25% 
patients; Fig. 2). Ongoing research in our laboratory is 
focused to better understand the functional consequences 
of the genetic variations in the exons 13 and 17 of BAP1 
gene. The detected nonsynonymous variations were signifi-
cantly correlated to the absence of BAP1 nuclear protein 
expression as assessed by IHC (Fig. 3). These data suggest 
that nonsynonymous variations identified affect BAP1 pro-
tein production and/or its stability and, according to pub-
lished studies, suggest that the lack of BAP1 protein is 
involved in MPM carcinogenesis.8 Furthermore, a recent 
study indicated that the absence of BAP1 causes accumula-
tion of mutations and chromosomal aberrations, leading to 
genomic instability.21
In the receptor tyrosine kinase–PI3K–AKT path-
way, already known cancer-associated mutations, such as 
PDGFRA (COSM22413),22 KIT (COSM28026),23 and KDR 
(COSM149673), were identified in 38, 26, and 38 samples, 
respectively. A HRAS silent genetic variation previously 
reported in bladder cancer (COSM249860)24 was identified in 
72 of 123 (58.5%) patients with MPM. More relevantly, a muta-
tion in the catalytic subunit of PI3K was detected and associ-
ated to disease progression. Indeed, 27 of 31 patients carrying 
the PIK3CA mutation I391M (COSM328028) had progressive 
disease as the best response to chemotherapy, suggesting a 
potential pathological role of this mutation in the natural his-
tory of MPM. These data match with previously published 
studies in which PI3K–AKT signaling was found activated in 
FIGURE 4. TP53 and PIK3CA genetic variations identified by next-generation sequencing (NGS) and correlation with time to 
progressive disease or overall survival (OS) of malignant pleural mesothelioma patients. A, TP53 rs1042522 genotype and time 
to progressive disease/OS. In left part of panel, the genotypes of three patients identified by NGS are shown and confirmed by 
Sanger sequencing. In details, the left panel shows Sanger electropherograms for rs1042522 homo- (C:C), hetero- (C:G), and 
homo-zygote (G:G) samples. In the middle panel, the same samples were represented by NGS sequence BAM files uploaded in 
IGV software. In the right panel, KaplanMeier curves show the association between rs1042522 genotype and the early disease 
progression or reduced survival (log-rank p value indicated in figure). B, PIK3CA mutation I391M and patient progression/OS. 
Left part of panel shows the high correlation between Sanger and NGS data when the allelic frequency for mutation was ≥15% 
at NGS. In the right part of the figure. KaplanMeier curves and contingency table show associations between PIK3CA p.I391M 
mutation and early disease progression (log-rank and Fisher test p values indicated in the figure).
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MPM, and a marker of therapy response. The detected genetic 
variation PIK3CA requires additional studies to evaluate if the 
change in the amino acid sequence may affect or deregulate the 
PIK3CA protein function and, as suggested by our data, asso-
ciated with a more aggressive type of MPM. Cacciotti et al.25 
suggested that PI3K–AKT pathway is involved in asbestos-
related mesothelioma carcinogenesis, increasing the survival 
of mesothelial cells after amosite exposure. Kim et al.26 dem-
onstrated that the inhibition of AKT activation through double 
PI3K–mTOR inhibitors enhanced apoptosis in human meso-
thelioma spheroids. In our study, PIK3CA nonsynonymous 
genetic variations with ≥10% AF were identified in 41 patients 
(33%), and these findings potentially support further studies 
specifically investigating the activity of PI3K–mTOR inhibi-
tors in this subgroup of MPM. Phase I/II studies are currently 
evaluating the role of double mTOR–PI3K inhibitors in several 
types of solid tumors,27 including MPM. GDC-0980, an oral 
PI3K–mTOR inhibitor, showed antitumor activity in MPM as 
evidenced by tumor regression and prolonged disease control.28
Mutations in two genes that affect mTOR regulation, 
STK11 and NF2, were also detected. Of note, the SNP varia-
tion rs2075606 in STK11 gene was correlated with shorter 
TTPD (see Supplemental Fig., Supplemental Digital Content 
3, http://links.lww.com/JTO/A755). NF2 that encodes for 
a protein called merlin,29,30 has been previously associated 
to MPM, whose inactivating mutations have been reported 
in up to 40% of the cases.29 NF2 nonsynonymous genetic 
variations were detected in 62 (50%) patients, and 15 had at 
least one mutation annotated in the COSMIC database (see 
Supplemental Table, Supplemental Digital Content 1, http://
links.lww.com/JTO/A753). No significant correlation was 
observed between NF2 genetic variations and, respectively, 
merlin IHC expression, others genes validated through Sanger 
sequencing and patients’ clinical pathological variables con-
sidered. These data might indicate that NF2 genetic variations 
identified and scattered across the gene could deregulate NF2 
without affecting protein expression/stability.
The interpretation of the results of this retrospective 
study has some limitations. First, there is a selection bias due to 
tissue availability because of asbestos workers’ compensation 
cases usually filed. The associated long-standing litigation fre-
quently comes with the request to provide MPM tissue blocks 
for external pathological confirmation or additional analy-
ses leading to tissue exhaustion. Second, although all known 
BAP1 and NF2 gene mutations were investigated through a 
custom-made panel, all the other genes were only assessed 
for the mutations included by manufacturer in Ion AmpliSeq 
Cancer Hotspot Panel v.2. Third, another limitation of the our 
study is represented by the assessment of gene mutations only, 
whereas other types of genetic changes, such as amplifica-
tion,31 wide genetic losses,8 or gene translocations,32 are not 
detected by the chosen technology. This makes complicated to 
compare the results of our study with those reported by others 
using a different sequencing technique. A previously reported 
study identified several nonsense and indels mutations often 
associated to protein changes,8 whereas, in the present study, 
we identified several point mutations that require additional 
functional characterization to assess putative effects on BAP1 
protein. Lastly, any observed association between a specific 
gene variation and the clinical outcome should be consid-
ered of borderline significance, especially in light of multiple 
potential interactions among mutations.
In conclusion, this is the first relatively large retrospective 
study of NGS for genetic characterization of MPM using FFPE 
archival material. Our results indicate a complex mutational 
status shooting mainly p53/DNA repair and PI3K–AKT path-
ways. In the present series, some of the genetic variations and 
their accumulation were associated with early progression of the 
tumor. Future studies should prospectively validate the prognos-
tic role of these genetic variations and, if confirmed, should be 
included among the stratification factors in future MPM studies.
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